首页> 美国卫生研究院文献>other >Approach to atypical Alzheimer’s disease and case studies of the major subtypes
【2h】

Approach to atypical Alzheimer’s disease and case studies of the major subtypes

机译:非典型阿尔茨海默氏病的治疗方法和主要亚型的病例研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alzheimer’s disease (AD) has long been recognized as a heterogeneous illness, with a common clinical presentation of progressive amnesia and less common “atypical” clinical presentations, including syndromes dominated by visual, aphasic, “frontal”, or apraxic symptoms. Our knowledge of atypical clinical phenotypes of AD comes from clinicopathologic studies, but with the growing use of in vivo molecular biomarkers of amyloid and tau pathology, we are beginning to recognize that these syndromes may not be as rare as once thought. When a clinician is evaluating a patient whose clinical phenotype is dominated by progressive aphasia, complex visual impairment, or other neuropsychiatric symptoms with relative sparing of memory, the differential diagnosis may be broader and a confident diagnosis of an atypical form of AD may require the use of molecular biomarkers. Despite the evolving sophistication in our diagnostic tools, and the acknowledgement of atypical AD syndromes in the 2011 revised diagnostic criteria for AD, the assessment of such patients still poses substantial challenges. We use a case-based approach to review the clinical and imaging phenotypes of a series of patients with typical and atypical AD, discussing our current approach to their evaluation. One day, we hope that regardless of whether a patient exhibits typical or atypical symptoms of AD pathology, we will be able to identify the condition at a prodromal or preclinical phase and institute a combination of symptomatic and disease-modifying therapies to support cognitive processes, function and behavior, and slow or halt progression to dementia.
机译:阿尔茨海默氏病(AD)长期以来一直被认为是一种异质性疾病,常见的临床表现为进行性健忘症,不常见的“非典型”临床表现包括以视觉,无视,“额叶”或肢端症状为主的综合症。我们对AD的非典型临床表型的了解来自临床病理学研究,但是随着淀粉样蛋白和tau病理学的体内分子生物标志物的使用日益广泛,我们开始认识到这些综合征可能并不像以前想象的那样罕见。当临床医生正在评估其临床表型以进行性失语,复杂视力障碍或其他神经精神症状为主且记忆相对较少的患者时,鉴别诊断可能会更广泛,对非典型形式的AD的可靠诊断可能需要使用分子生物标志物。尽管我们的诊断工具日趋完善,并且在2011年修订的AD诊断标准中承认了非典型AD综合征,但对此类患者的评估仍面临巨大挑战。我们使用基于案例的方法来审查一系列典型和非典型AD患者的临床和影像学表型,讨论我们目前对其评估的方法。希望有一天,我们希望无论患者表现出AD病理的典型症状还是非典型症状,我们都能够在前驱阶段或临床前阶段确定病情,并建立对症和疾病缓解疗法的组合以支持认知过程,功能和行为,并延缓或停止发展为痴呆症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号